Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder of Zhejiang Aokang Shoe Industry Co., Ltd., indicating a significant portion of shares are pledged, but it does not impact the company's operations or governance. Group 1: Share Pledge Details - The controlling shareholder, Aokang Investment Holding Co., Ltd., holds 111,181,000 shares, accounting for 27.73% of the total share capital, with a cumulative pledge of 89,610,100 shares, representing 80.60% of its holdings [2][3] - Aokang Investment and its concerted actor, Mr. Wang Zhentao, collectively hold 171,737,717 shares, which is 42.83% of the total share capital, with a total pledge of 149,610,100 shares, equating to 87.12% of their holdings [2][3] Group 2: Specifics of the Pledge - On July 25, 2025, Aokang Investment pledged 12,500,000 shares to Shanghai Wankexin Biotechnology Partnership [3] - The pledged shares are not used for major asset restructuring or performance compensation guarantees [3] Group 3: Impact on the Company - The share pledge will not affect the company's main business, financing credit, financing costs, or ongoing operational capabilities [5] - There will be no impact on corporate governance, as the controlling shareholder and its concerted actor operate independently from the company [6] - The pledge does not involve any performance compensation obligations from the controlling shareholder [7] - The pledge is classified as a non-financing pledge [8] Group 4: Financial Health of the Controlling Shareholder - Aokang Investment was registered on October 10, 2009, with a registered capital of 100 million RMB [9] - The controlling shareholder has no bond issuance and is not involved in significant litigation or arbitration related to debt issues [10] - Aokang Investment maintains normal operations and has established good relationships with major securities firms and commercial banks for financing [10] Group 5: Transactions with the Company - In the past year, there have been no significant financial transactions, related party transactions, or external guarantees between Aokang Investment and the company, aside from the company's equity distribution [11]

Group 1 - The company announced that its controlling shareholder, Aokang Investment, has pledged 12.5 million shares, which is 11.24% of its holdings, for financing purposes [1][2][3] - As of the announcement date, Aokang Investment and its concerted party, Wang Zhentao, have a total of 149.61 million pledged shares, representing 87.12% of their total holdings [2][3] - Aokang Investment holds 111.81 million shares, accounting for 27.73% of the company's total share capital, with a cumulative pledge of 89.61 million shares [3][4] Group 2 - The pledged shares do not affect the company's main business operations, financing costs, or ongoing viability [4][5] - Aokang Investment has no upcoming due pledges within the next year, indicating a stable financial position [4][6] - The company maintains a good relationship with major securities firms and commercial banks, ensuring access to financing channels [6][7] Group 3 - The company has distributed cash dividends to Aokang Investment, amounting to 1,334.17 million yuan and 1,667.72 million yuan in 2024 [7] - There are no significant transactions or related party dealings between Aokang Investment and the company that could harm the company's interests [7]

证券代码：603001 证券简称：奥康国际 公告编号：临 2025-024 浙江奥康鞋业股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次股份质押的具体情况 公司于 2025 年 7 月 28 日接到公司控股股东的通知，获悉其于 2025 年 7 月 25 日将其持有的本公司无限售条件流通股 12,500,000 股股份质押给上海万可欣 生物科技合伙企业（有限合伙）（以下简称"上海万可欣"）。现将具体情况公 告如下： | 股东名称 | 是否为 控股股 | 本次质押股 | 是否为 | 是否 补充 | 质押起始 | 质押到期日 | 质权 | 占其所 持股份 | 占公司 总股本 | 质押融资资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东 | 数（万股） | 限售股 | 质押 | 日 | | 人 | 比例 | 比例 | 金用途 | | 奥康投资 | 是 | 12 ...

New Stock Issuance - HanSang Technology (301491) issued at a price of 28.91 on July 25, 2025[1] - ST Kelly (300326) has a tender offer period from July 17 to August 15, 2025[1] - ST Zitian (300280) reported significant fluctuations on July 21, 2025[1] Market Alerts - Deepwater Regulation Institute (301038) reported severe abnormal fluctuations on July 24, 2025[1] - Guangsheng Tang (300436) announced significant market activity on July 17, 2025[1] - Huayin Power (600744) has been flagged for unusual trading patterns on July 15, 2025[1] Other Notable Stocks - Jiangnan Chemical (002226) reported trading activity on July 23, 2025[3] - China Electric Power Construction (601669) had a trading update on July 25, 2025[3] - Tibet Tourism (600749) reported significant trading activity on July 25, 2025[3]

Group 1 - The stock of Aokang International (603001) fell by 7.33% today, with a turnover rate of 5.26% and a trading volume of 177 million yuan, showing a fluctuation of 7.73% [2] - The stock was listed on the Shanghai Stock Exchange due to a daily decline deviation of -8.05%, with a net selling amount of 13.94 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 69.88 million yuan, with a buying amount of 27.97 million yuan and a selling amount of 41.91 million yuan, resulting in a net selling of 13.94 million yuan [2] Group 2 - The main buying brokerage was Guotai Junan Securities Headquarters, with a buying amount of 10.19 million yuan, while the largest selling brokerage was Changcheng Securities Hangzhou Wenyixi Road, with a selling amount of 12.83 million yuan [2] - The stock experienced a net outflow of 7.35 million yuan in main funds today, with a significant single net outflow of 3.33 million yuan and a large single fund net outflow of 4.02 million yuan [2] - Over the past five days, the main funds have seen a net inflow of 16.27 million yuan [2] Group 3 - On April 30, the company released its Q1 report, showing a total revenue of 590 million yuan, a year-on-year decrease of 22.30%, and a net profit of -44.06 million yuan [2] - On July 12, the company announced a half-year performance forecast, expecting a net profit of -87 million yuan [3]

New Stock Issuance - The new stock issued by Hanguo Group is priced at 15.43 RMB per share[1] - The subscription period for the tender offer of ST Kelly is from July 17, 2025, to August 15, 2025[1] Abnormal Fluctuations - Several stocks, including ST Zitian and Guangshengtang, have reported severe abnormal fluctuations[2] - The announcement links for stocks experiencing abnormal fluctuations are provided for investor reference[2] Market Updates - A total of 30 stocks have been listed for trading updates, with various announcements made between July 15 and July 21, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1]

Core Viewpoint - The actual controller of Kanghua Biological (300841.SZ), Wang Zhentao, is planning to transfer control of the company, marking a significant turning point for the once-prominent vaccine enterprise that had a market value exceeding 50 billion yuan [1][2]. Company Overview - Kanghua Biological was established in 2004 by Wang Zhentao and a core vaccine research team, and it went public in 2020, reaching a peak market value of over 50 billion yuan [5][6]. - The company achieved revenue of 1.04 billion yuan and a net profit of 410 million yuan in 2020, with its stock price peaking at 414 yuan [6]. Financial Performance - Since 2022, Kanghua Biological has experienced declining revenues and profits, with 2024 revenue reported at 1.432 billion yuan, a year-on-year decrease of 9.23%, and net profit at 399 million yuan, down 21.71% [6]. - The first quarter of 2025 showed continued poor performance, with total revenue of 138 million yuan, a year-on-year decline of 55.7%, and net profit of approximately 20.71 million yuan, down 86.14% [6]. Shareholder Actions - Prior to the announcement of the control change, Kanghua Biological faced significant shareholder reductions, with two venture capital firms planning to reduce their holdings by up to 316,580 shares, representing 2.44% of the total shares [7]. Wang Zhentao's Business Challenges - Wang Zhentao has faced multiple failures in cross-industry investments, including a significant loss of over 200 million yuan in a cross-border e-commerce platform and a failed semiconductor acquisition in 2024 [3][12]. - The financial strain on Wang Zhentao is evident, with cumulative pledges of shares in both Kanghua Biological and Aokang International reaching 89.2% and 71.91% respectively [16][17]. Regulatory Issues - Wang Zhentao and related companies faced regulatory penalties in 2024 for non-operational fund occupation, with amounts involved reaching 1.67 billion yuan and 950 million yuan over two years [17].

证券代码：603001 证券简称：奥康国际 公告编号：临 2025-023 浙江奥康鞋业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律连带责任。 重要提示： ● 浙江奥康鞋业股份有限公司（以下简称"公司"）股票于 2025 年 7 月 11 日、7 月 14 日、7 月 15 日连续 3 个交易日内收盘价格涨幅偏离值累计达到 20%，根据《上海证券交易所交易规则》相关规定，属于股票交易异常波动的情 形。 ● 经公司自查并向控股股东及实际控制人书面核实，截止本公告披露日， 除已公开披露的事项外，公司、控股股东及实际控制人不存在应披露而未披露 的重大信息。 ● 公司预计 2025 年半年度实现归属于母公司所有者的净利润约为-8,700 万元，与上年同期相比，亏损加大。敬请广大投资者理性投资，注意二级市场 交易风险。 一、股票交易异常波动的具体情况 公司股票交易于 2025 年 7 月 11 日、7 月 14 日、7 月 15 日连续 3 个交易日 内日收盘价格涨幅偏离值累计达到 20%，根据《上海证券 ...

Core Viewpoint - Wang Zhentao, the founder of Aokang International, is facing significant financial difficulties due to failed cross-industry ventures, leading to plans to transfer control of Kanghua Biological, a company he established, to alleviate cash flow pressures [1][2][6]. Group 1: Financial Performance - Kanghua Biological reported a revenue of 14.32 billion yuan in 2024, a year-on-year decline of 9.23%, and a net profit of 3.99 billion yuan, down 21.71% [2]. - In the first quarter of 2025, Kanghua Biological's total revenue was 1.38 billion yuan, a decrease of 55.7%, with a net profit of 20.71 million yuan, down 86.14% [3]. - The stock price of Kanghua Biological has dropped significantly from a peak of 414 yuan to 72.01 yuan per share, resulting in a market capitalization reduction to 9.574 billion yuan [3]. Group 2: Ownership and Control Changes - Wang Zhentao is planning to transfer control of Kanghua Biological, which has been a significant part of his business portfolio since its establishment in 2004 [2]. - The stock of Kanghua Biological was suspended from trading starting July 14 due to the announcement of the potential change in control [2]. Group 3: Investment Losses and Challenges - Aokang International has incurred substantial losses from various investments, including over 200 million yuan in a cross-border e-commerce platform and a failed semiconductor acquisition [1][4][5]. - The company has reported net losses of 679 million yuan over the past three years, indicating ongoing financial struggles [1][6]. Group 4: Share Pledge and Regulatory Issues - Wang Zhentao has pledged a significant portion of his shares in both Aokang International and Kanghua Biological, with 89.2% and 71.91% of shares pledged, respectively [7]. - Regulatory penalties were imposed on Wang Zhentao and related companies for misappropriating funds from Aokang International, totaling 1.67 billion yuan and 950 million yuan in 2021 and 2022 [8].

Summary of Key Points Core Viewpoint - Zhejiang Aokang Footwear Co., Ltd. expects a significant net loss of approximately 87 million yuan for the first half of 2025, primarily due to macroeconomic downturns, weak consumer demand, and intensified industry competition [1]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of approximately -87 million yuan for the first half of 2025 [1]. - The previous year's net profit attributable to shareholders was -19.83 million yuan, with a net profit of -57.57 million yuan after deducting non-recurring gains and losses [1]. - The expected revenue for the current period is 1.081 billion yuan, representing a decline of about 21% compared to the same period last year [1]. Group 2: Financial Status - The company reported a loss per share of -0.0494 yuan in the previous year [1]. - The current performance forecast has not been audited by a registered accounting firm [1].